Fanconi anemia

Cells continually repair damage to their DNA. In Fanconi anemia, part of that repair system does not work normally. Blood-forming stem cells are especially vulnerable, which can lead to falling blood counts or abnormal marrow cells.

Some people have differences in growth, skin pigmentation, thumbs, kidneys or other organs. Others have few outward signs. Diagnosis may occur in childhood or adulthood and uses chromosome-breakage testing, genetic testing and clinical assessment.

Most forms involve disease-causing changes in both copies of a Fanconi-related gene. There are also X-linked and rare dominant forms. A genetic counselor can explain what the identified variant means for the family; the inheritance pattern cannot be inferred from the name alone.

A person carrying one variant associated with recessive Fanconi anemia usually does not have Fanconi anemia. However, some of these genes, including BRCA-related genes, also confer cancer susceptibility in carriers. Family testing therefore needs gene-specific interpretation.

Declining red cells can cause anemia, low platelets can cause bleeding, and low neutrophils can increase infection risk. Fanconi anemia also increases the risk of myelodysplastic neoplasms, leukemia and certain solid tumors.

The course varies. The absence of visible physical differences does not rule out marrow or cancer risk, and an abnormal blood count does not by itself establish leukemia. Monitoring is intended to identify changes before complications become severe.

Care combines blood and marrow monitoring, cancer surveillance and treatment of organ-specific problems. Transfusions, infection treatment and sometimes androgen therapy can support blood production, but do not repair the underlying genetic defect.

Allogeneic transplantation is considered for significant marrow failure or concerning myelodysplastic or leukemic changes. Conditioning must be adapted because Fanconi cells are unusually sensitive to DNA-damaging treatment. The transplant team balances disease control, graft failure and treatment toxicity.

Successful transplantation can restore blood production. Congenital differences, endocrine problems and solid-tumor susceptibility still require care. Cancer surveillance continues after transplant.

Care may involve hematology, genetics and several organ specialists. Appointments can include growth and hormone assessment, oral and skin examination and monitoring of hearing, kidneys or other affected organs.

Families may need help coordinating these visits with school, work and daily life. A transplant adds preparation, hospital treatment and prolonged follow-up; its benefit is weighed alongside both early complications and late effects. People’s care needs and priorities differ.

A suitable related or unrelated donor can provide the blood-forming cells for transplantation. A close HLA match is important, but a related donor must also be assessed for Fanconi anemia even if they feel well and have normal blood counts.

A registry search is a meaningful option when an appropriate family donor is unavailable. Donor cells treat the blood-forming system; they cannot be described as a cure for every manifestation of Fanconi anemia.

What is the exact diagnosis or subtype? What is the goal of each treatment option? If transplant is being considered, why does it fit this situation, which cells would be used and what are the alternatives?